Evaluation of the Efficacy of Computed Tomographic Coronary Angiography in Assessing Coronary Artery Morphology and Physiology: Rationale and Study Design.

Atherosclerosis Computed tomographic coronary angiography Local haemodynamic forces Near-infrared spectroscopy-intravascular imaging

Journal

Cardiology
ISSN: 1421-9751
Titre abrégé: Cardiology
Pays: Switzerland
ID NLM: 1266406

Informations de publication

Date de publication:
2020
Historique:
received: 18 04 2019
accepted: 12 02 2020
pubmed: 15 4 2020
medline: 13 6 2020
entrez: 15 4 2020
Statut: ppublish

Résumé

Computed tomographic coronary angiography (CTCA) is a non-invasive imaging modality, which allows plaque burden and composition assessment and detection of plaque characteristics associated with increased vulnerability. In addition, CTCA-based coronary artery reconstruction enables local haemodynamic forces assessment, which regulate plaque formation and vascular inflammation and prediction of lesions that are prone to progress and cause events. However, the use of CTCA for vulnerable plaque detection in the clinical arena remains limited. To unlock the full potential of CTCA and enable its broad use, further work is needed to develop user-friendly processing tools that will allow fast and accurate analysis of CTCA, computational fluid dynamic modelling, and evaluation of the local haemodynamic forces. The present study aims to develop a seamless platform that will overcome the limitations of CTCA and enable fast and accurate evaluation of plaque morphology and physiology. We will analyse imaging data from 70 patients with coronary artery disease who will undergo state-of-the-art CTCA and near-infrared spectroscopy-intravascular ultrasound imaging and develop and train algorithms that will take advantage of the intravascular imaging data to optimise vessel segmentation and plaque characterisation. Furthermore, we will design an advanced module that will enable reconstruction of coronary artery anatomy from CTCA, blood flow simulation, shear stress estimation, and comprehensive visualisation of vessel pathophysiology. These advances are expected to facilitate the broad use of CTCA, not only for risk stratification but also for the evaluation of the effect of emerging therapies on plaque evolution.

Identifiants

pubmed: 32289784
pii: 000506537
doi: 10.1159/000506537
doi:

Types de publication

Journal Article Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

285-293

Subventions

Organisme : Department of Health
ID : DRF-2014-07-008
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/17/18/32883
Pays : United Kingdom

Commentaires et corrections

Type : CommentOn

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Anantharaman Ramasamy (A)

Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.
William Harvey Research Institute, Queen Mary University London, London, United Kingdom.

Hannah Safi (H)

Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.
Department of Mechanical Engineering, University College London, London, United Kingdom.

James C Moon (JC)

Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.
Institute of Cardiovascular Sciences, University College London, London, United Kingdom.

Mervyn Andiapen (M)

Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.

Krishnaraj S Rathod (KS)

Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.
William Harvey Research Institute, Queen Mary University London, London, United Kingdom.

Pal Maurovich-Horvat (P)

MTA-SE Lendulet Cardiovascular Imaging Research Group, Heart and Vascular Centre, Semmelweis University, Budapest, Hungary.

Retesh Bajaj (R)

Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.
William Harvey Research Institute, Queen Mary University London, London, United Kingdom.

Patrick W Serruys (PW)

Faculty of Medicine, National Heart & Lung Institute, Imperial College London, London, United Kingdom.

Anthony Mathur (A)

Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.
William Harvey Research Institute, Queen Mary University London, London, United Kingdom.

Andreas Baumbach (A)

Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.
William Harvey Research Institute, Queen Mary University London, London, United Kingdom.

Francesca Pugliese (F)

Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.
William Harvey Research Institute, Queen Mary University London, London, United Kingdom.

Ryo Torii (R)

Department of Mechanical Engineering, University College London, London, United Kingdom.

Christos V Bourantas (CV)

Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom, cbourantas@gmail.com.
William Harvey Research Institute, Queen Mary University London, London, United Kingdom, cbourantas@gmail.com.
Institute of Cardiovascular Sciences, University College London, London, United Kingdom, cbourantas@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH